Anita T. Shaffer

During the past 40 years, the concept of thwarting a tumor by attacking its blood supply has become a central thrust of cancer research, a strategy that reached a milestone with the approval of bevacizumab in 2004.

Despite controversy over its breast cancer approval status, bevacizumab (Avastin) remains at center stage when it comes to antiangiogenic therapies for the disease.

Professor of Surgery and Consultant Surgeon at the University of Edinburgh; and Clinical Director of the Edinburgh Breast Unit at the Western General Hospital in Edinburgh, Scotland.

Detecting breast cancer using mammography and self-examination was affirmed in a study that sharply contrasts the controversial 2009 USPSTF recommendations.

A new set of statistical models will soon be available to help predict the risk of lymphedema for patients with breast cancer who have undergone ALND.

Women age 40 and younger with breast cancer experience similar outcomes in local recurrence and survival rates whether they undergo BCT or a mastectomy.

Amid a continuing emphasis on targeted therapies, pharmaceutical companies have approximately 300 drugs in phase II or later-stage development for cancer treatment.

Every decade during the past 50 years, treatment for multiple myeloma has taken a leap forward.

The American College of Obstetricians and Gynecologists this week recommended annual mammography screenings for women starting at age 40.

Researchers are continuing to explore whether ixabepilone (Ixempra) is a better choice as adjuvant chemotherapy for patients with early-stage, triple-negative breast cancer than the standard paclitaxel (Taxol).

Even before the FDA approved ipilimumab in March, the field of cancer immunotherapy was a lively area of scientific inquiry.

Crizotinib demonstrated marked antitumor activity among patients with advanced ALK-positive non–small cell lung cancer.

Breast cancer survivors age 66 and older are more likely to die of cardiovascular disease (CVD) than they are of the cancer itself.

Vismodegib has demonstrated positive overall response rates in patients with advanced basal cell carcinoma.

The FDA has granted accelerated approval for Istodax (romidepsin) to be used as treatment for an aggressive form of non-Hodgkin lymphoma

Clinical observations are more effective than routine testing in posttreatment surveillance and diagnosis of most gynecologic tumors

Radiation therapy (RT) used in combination with hormonal approaches continues to be a viable strategy for treating localized, high-risk prostate cancer patients

Hormonal therapies have long been the standard of care for metastatic advanced prostate cancer

PROSTVAC-VF uses the smallpox viral vector to stimulate the immune system.

Axitinib demonstrated significantly better progression-free survival (PFS) compared with sorafenib

New treatment approaches that improve overall survival for patients with late-stage melanoma spotlighted

Radiation therapy directed to the regional lymph nodes of women with early-stage breast cancer reduced distant disease recurrence

Many clinicians are not employing radiation therapy used in combination with androgen deprivation therapy even though guidelines suggest they should

The amount of money spent in the United States on oncology drugs is expected to rise from 8% to 15% a year through 2013

Oncology specialists, biopharmaceutical analysts and investors all await the latest research news from the upcoming ASCO annual meeting

A genetic analysis resulted in the discovery of the first predictive biomarker for taxane-induced peripheral neuropathy

The oncology community is paying fresh attention to the often painful skeletal-related events in patients with bone metastases.

ASTRO has for the first time issued its own extensive guidelines for the use of palliative thoracic radiotherapy in patients with metastatic lung cancer

Revlimid (lenalidomide) has demonstrated dramatic, long-term benefits as a second-line therapy for patients with multiple myeloma

Afinitor is now approved for the treatment of pancreatic neuroendocrine tumors in patients with unresectable, locally advanced, or metastatic disease